Aldeyra Therapeutics

Wooden blocks with arrow and error icon Delays and disruptions stop the process critical error concept
Biotech

FDA rejects Aldeyra eye disease candidate for 3rd time

AbbVie has an option agreement for reproxalap, making Aldeyra eligible for a $100 million payment if the FDA approves the drug in dry eye disease.
Gabrielle Masson Mar 17, 2026 11:12am
Abstract modern white spiral clock dial with roman and arabic numerals

Aldeyra dry eye disease decision hit by FDA delay

Dec 16, 2025 11:55am
decision path change of plans arrows business decision

Aldeyra drops and swaps RASP assets in response to data

Oct 28, 2025 9:10am
eye eyeball eye art

Aldeyra posts hit, miss for dry eye drug, plans FDA filing

May 6, 2025 7:05am
Graphic image of a red thumbs down against a blue background

Aldeyra’s dry eye drug suffers second FDA rejection

Apr 3, 2025 8:46am
eye drops

Aldeyra preps for FDA refiling as dry eye drug hits ph. 3 goal

Aug 8, 2024 10:48am